SEATTLE, Wash. and VANCOUVER, British Columbia, May 23, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, May 9, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced first quarter 2018 financial results and recent highlights. First-Quarter 2018 Highlights Announced preliminary results from a Phase I/II clinical study evaluating…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, May 7, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that the UK Intellectual Property Office has granted Achieve a patent (no. 2550241) on cytisine succinate salt. Cytisine is a plant-based…
/Read More
BOTHELL, Wash. and VANCOUVER, British Columbia, March. 6, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced that the World Conference on Tobacco or Health (WCTOH) will be holding a symposium on cytisine research at this year’s annual conference, March 7-9th in Cape Town, South Africa. The cytisine symposium titled “Is a Globally…
/Read More
BOTHELL, Wash and VANCOUVER, British Columbia, March 1, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today highlighted recent accomplishments and announced fourth quarter and year-end 2017 financial results. Recent Highlights Announced preliminary results from clinical study evaluating pharmacokinetic…
/Read More